U. Holwerda

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers

Paul Noordhuis, U. Holwerda, C.L. van der Wilt et al. · Annals of Oncology · 2004 · 257 citations · Full text

Oncogenic Agent, Synthase Inhibition, Molecular Biology +6

Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid β-oxidation disorders

Catarina G. Costa, L. Dorland, U. Holwerda et al. · Clinical Chemistry · 1998 · 99 citations · Full text

Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.

M. Treskes, Epie Boven, U. Holwerda et al. · PubMed · 1992 · 66 citations

Formulated Wr2721, Pharmacotherapy, Cisplatin Dose +17

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors

Godefridus J. Peters, Paul Noordhuis, André B. P. Kuilenburg et al. · Cancer Chemotherapy and Pharmacology · 2003 · 52 citations

Solid Tumors, Medicine, Pharmacology +9

Quantitative analysis of urinary acylglycines for the diagnosis of β-oxidation defects using GC-NCI-MS

C. G. Costa, W. S. Guérand, Edward A. Struys et al. · Journal of Pharmaceutical and Biomedical Analysis · 2000 · 47 citations · Full text

Urinary Acylglycines, Urology, Biochemistry +6